



HARTINGTON
PHARMA LTD

TO WHOM IT MAY CONCERN

DECLARATION OF CONFORMITY

The undersigned Alex Levdanki, as President of Hartington Pharma LTD, with office is at 1 Northumberland Ave., Trafalgar Square, London WC2N 5BW, UK, registration number 06134802

DECLARES

The medical device NASODREN®

Was placed on the market by this company on March 2007 under the Directive 93/42/EEC of 14 June 1993

Since March 2007 and until the new Medical Device Regulation has entered in force, Nasodren has been on the market as a class I non-sterile medical device pursuant to rule 5 of appendix IX of the Directive 93/42/EEC.

Following the Medical Device Regulation 2017/745, Nasodren, nasal spray, remains under a class I pursuant rule 5 of appendix IX, all invasive devices with respect to body orifices as invades de nasal body orifice and its intended use is a transient use that last for less than 60 minutes.

Signed

Alex Levdanki
President

A handwritten signature in blue ink, consisting of several overlapping loops and a long horizontal stroke at the bottom.